872 related articles for article (PubMed ID: 25807090)
1. Does starting allopurinol prolong acute treated gout? A randomized clinical trial.
Hill EM; Sky K; Sit M; Collamer A; Higgs J
J Clin Rheumatol; 2015 Apr; 21(3):120-5. PubMed ID: 25807090
[TBL] [Abstract][Full Text] [Related]
2. Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial.
Taylor TH; Mecchella JN; Larson RJ; Kerin KD; Mackenzie TA
Am J Med; 2012 Nov; 125(11):1126-1134.e7. PubMed ID: 23098865
[TBL] [Abstract][Full Text] [Related]
3. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
Schumacher HR; Evans RR; Saag KG; Clower J; Jennings W; Weinstein SP; Yancopoulos GD; Wang J; Terkeltaub R
Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1462-70. PubMed ID: 22549879
[TBL] [Abstract][Full Text] [Related]
4. Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial.
Schumacher HR; Sundy JS; Terkeltaub R; Knapp HR; Mellis SJ; Stahl N; Yancopoulos GD; Soo Y; King-Davis S; Weinstein SP; Radin AR;
Arthritis Rheum; 2012 Mar; 64(3):876-84. PubMed ID: 22223180
[TBL] [Abstract][Full Text] [Related]
5. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.
Hosoya T; Ogawa Y; Hashimoto H; Ohashi T; Sakamoto R
J Clin Pharm Ther; 2016 Jun; 41(3):290-7. PubMed ID: 27109450
[TBL] [Abstract][Full Text] [Related]
6. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL
Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
Sundy JS; Baraf HS; Yood RA; Edwards NL; Gutierrez-Urena SR; Treadwell EL; Vázquez-Mellado J; White WB; Lipsky PE; Horowitz Z; Huang W; Maroli AN; Waltrip RW; Hamburger SA; Becker MA
JAMA; 2011 Aug; 306(7):711-20. PubMed ID: 21846852
[TBL] [Abstract][Full Text] [Related]
8. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.
Stamp LK; Taylor WJ; Jones PB; Dockerty JL; Drake J; Frampton C; Dalbeth N
Arthritis Rheum; 2012 Aug; 64(8):2529-36. PubMed ID: 22488501
[TBL] [Abstract][Full Text] [Related]
9. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
Wortmann RL; Macdonald PA; Hunt B; Jackson RL
Clin Ther; 2010 Dec; 32(14):2386-97. PubMed ID: 21353107
[TBL] [Abstract][Full Text] [Related]
10. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.
Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
Clin Pharmacol Ther; 2011 Sep; 90(3):392-8. PubMed ID: 21796116
[TBL] [Abstract][Full Text] [Related]
11. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).
Bardin T; Keenan RT; Khanna PP; Kopicko J; Fung M; Bhakta N; Adler S; Storgard C; Baumgartner S; So A
Ann Rheum Dis; 2017 May; 76(5):811-820. PubMed ID: 27821644
[TBL] [Abstract][Full Text] [Related]
12. Serum urate during acute gout.
Schlesinger N; Norquist JM; Watson DJ
J Rheumatol; 2009 Jun; 36(6):1287-9. PubMed ID: 19369457
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with acute gout attacks in normouricaemic gout patients receiving allopurinol: a retrospective study.
So MW; Lee SG; Kim YG; Lee CK; Yoo B
Scand J Rheumatol; 2011 Nov; 40(6):444-7. PubMed ID: 21916803
[TBL] [Abstract][Full Text] [Related]
14. Significance of the initiation time of urate-lowering therapy in gout patients: A retrospective research.
Feng X; Li Y; Gao W
Joint Bone Spine; 2015 Dec; 82(6):428-31. PubMed ID: 26456042
[TBL] [Abstract][Full Text] [Related]
15. A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift.
Khanna P; Khanna D; Storgard C; Baumgartner S; Morlock R
Postgrad Med; 2016 Jan; 128(1):34-40. PubMed ID: 26578028
[TBL] [Abstract][Full Text] [Related]
16. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial.
Mitha E; Schumacher HR; Fouche L; Luo SF; Weinstein SP; Yancopoulos GD; Wang J; King-Davis S; Evans RR
Rheumatology (Oxford); 2013 Jul; 52(7):1285-92. PubMed ID: 23485476
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study.
Hosoya T; Sasaki T; Ohashi T
Clin Rheumatol; 2017 Mar; 36(3):649-656. PubMed ID: 27832384
[TBL] [Abstract][Full Text] [Related]
18. A Randomized, Double-Blind, Active- and Placebo-Controlled Efficacy and Safety Study of Arhalofenate for Reducing Flare in Patients With Gout.
Poiley J; Steinberg AS; Choi YJ; Davis CS; Martin RL; McWherter CA; Boudes PF;
Arthritis Rheumatol; 2016 Aug; 68(8):2027-34. PubMed ID: 26989892
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions.
Chohan S
J Rheumatol; 2011 Sep; 38(9):1957-9. PubMed ID: 21724706
[TBL] [Abstract][Full Text] [Related]
20. Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial.
Stamp L; Horne A; Mihov B; Drake J; Haslett J; Chapman PT; Frampton C; Dalbeth N
Ann Rheum Dis; 2023 Dec; 82(12):1626-1634. PubMed ID: 37652661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
